No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK reported new earlystage global data for risvutatug rezetecan (RisRez), an experimental cancer treatment being tested in patients with relapsed smallcell lung cancer.
In a phase Ib study, GSK said the drug produced a 61% response rate at the higher 8mg/kg dose, compared with 32% at 6mg/kg. GSK said the results, which will be presented at the ESMO 2026 congress in Madrid, support using the 8mg/kg dose in its ongoing global phase III trial.
The FTSE 100-listed company said the treatment's sideeffect profile was manageable, with most issues linked to bloodrelated conditions. More serious side effects occurred in 42% of patients at the higher dose and 15% at the lower dose. One case of interstitial lung disease was reported across 50 patients.
GSK's Hesham Abdullah said: "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options."
As of 0905 BST, GSK shares were up 0.16% at 1,865.50p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS on Sharecast
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.